Nestlé Acquires CM&D Pharma Limited

CM&D Pharma Limited, founded in 2007 by its President Danilo Casadei Massari and progressed in collaboration with CEO Stephen Appelbee, is focussing on the development and commercialisation of innovative products for the dietary management of widespread conditions.

2/3/2011 --- CM&D Pharma Limited has announced that Nestlé has completed the acquisition of the Company for an undisclosed sum.

CM&D Pharma Limited, founded in 2007 by its President Danilo Casadei Massari and progressed in collaboration with CEO Stephen Appelbee, is focussing on the development and commercialisation of innovative products for the dietary management of widespread conditions.

Chronic Kidney Disease (CKD), where Fostrap has already shown promise, Irritable Bowel Syndrome (IBS), where Recoclix is included in a long-term multicentre study and Colon Adenopolyposis, where Eviendep(R) is currently completing a pivotal clinical trial, are the key areas of development , and all the Company’s ongoing clinical trials are expected to report in 2011.

CM&D Founder, Danilo Casadei Massari, commented: “The Board of CM&D Pharma is confident that now, with a trade shareholder with unparalleled expertise and understanding of the science and the regulatory environment behind dietary management of health conditions, its product portfolio will be fully exploited. We are also pleased to have maintained our promise to our original shareholders, and rewarded them for their faith in us.”

Fasken Martineau LLP acted as legal adviser to CM&D on the transaction.